The abnormal status of uncarboxylated @entity9198 species represents an additional mortality risk in @entity712 @entity1 with XXXX .

@entity1 @entity712 @entity455 @entity3876 @entity9198 @entity730 @entity2018
BACKGROUND: @entity9198 ( @entity9198 ) is a natural inhibitor of tissue @entity730 . In a previous study, we observed the positive association between abnormal concentrations of uncarboxylated @entity9198 species and increased mortality risk in stable vascular @entity1 . We explore whether co-incidence of abnormal status of uncarboxylated @entity2018 and @entity712 ( @entity712 ) affects the mortality risk. METHODS: We examined 799 @entity1 (mean age 65.1years) with stable @entity455 and followed them in a prospective study. Both, desphospho-uncarboxylated and total uncarboxylated @entity9198 (dp-ucMGP or t-ucMGP) were quantified by pre-commercial ELISA assays. RESULTS: Elevated (>100ng/L) circulating @entity3876 ( @entity3876 ) and abnormal status of plasma uncarboxylated @entity9198 species (i.e.: dp-ucMGP >= 977pmol/L or t-ucMGP <=2825nmol/L) were all identified as robust predictors of all-cause 5-year mortality. However, their co-incidence represented a substantial additional risk. We observed the highest mortality risk in @entity1 with elevated @entity3876 plus high dp-ucMGP compared to those with normal @entity3876 plus low dp-ucMGP; fully adjusted HRR's were 4.86 (3.15-7.49). Likewise, the risk was increased when compared with @entity1 with elevated @entity3876 plus low dp-ucMGP; HRR 2.57 (1.60-4.10). Similar result we observed when co-incidence of elevated @entity3876 and low t-ucMGP was analyzed [corresponding HRR's were 4.16 (2.62-6.61) and 1.96 (1.24-3.12)]. CONCLUSIONS: The concomitant abnormality of uncarboxylated @entity9198 and mild elevation of @entity3876 leads in chronic @entity1 with @entity455 to about two-fold increase of the relative mortality risk. We hypothesize that abnormal homeostasis of @entity9198 is involved in the pathophysiology of @entity712 .
